Findings indicate that COPD has a substantial physical and psychosocial impact on patients, particularly those aged 45–54 years old. Compared with older patients (≥65 years old), this group more frequently reported that their COPD has a higher impact on their wellbeing and daily activities, and reported making more frequent adjustments to their activity due to their symptoms.1 Survey results indicate that there are significant quality of life and educational unmet needs, particularly amongst younger people living with COPD.
“This is one of the few surveys that looks at the impact of COPD in different age groups,” said Professor Dr Dekhuijzen, Pulmonologist, Radboud University Medical Center, Nijmegen, The Netherlands. “As healthcare professionals, we have to realise that the same disease has a different impact in younger and older patients, and that the perceived impact has to be addressed to tailor and optimise treatment to suit each patient.”
When looking specifically at the outcomes reported by younger patients (45–54 years old) versus older patients (≥65 years old):
Younger patients more frequently reported that their COPD ‘extremely’ or ‘very much’ impacts their ability to carry out tasks outside the home (37% vs 22%) and travel long distances (38% vs 18%),1 and they were more than twice as likely to need to plan their day around periods of breathlessness and/or coughing (41% vs 19%)1
A significantly higher proportion of patients aged 45–54 years old reported “poor” or “very poor” wellbeing (35% vs 28%; P<0.05), and reported feeling “stressed” and “overwhelmed” 1.7 and 2.2 times more frequently (P<0.05), respectively1
Reliance on physicians was more significant amongst younger patients, who were more than three times more likely to want information to aid them to better manage using their inhaler device (18% vs 58% did not want this type of information)1
“One possible explanation as to why the perceived burden differs strongly is that younger patients are usually more active in terms of their work and social life, and so have differing expectations about what life with COPD will be,” said Nicole Hass, Representative from the European Federation of Allergy and Airways Diseases Patients’ Associations (EFA). “Although more research is needed to better understand why these age differences exist, these findings show we need to make patients more aware of how they can positively impact their disease progression through things like speaking to clinicians about optimal treatment aimed at keeping them active in their daily lives.”
Findings reinforce the need for HCPs and COPD patients, particularly younger ones, to work towards optimal treatment management and therapy aimed at improving symptoms and lessening the impact of the disease on patients’ quality of life. According to Dr. Paola Casarosa, Head of Global Therapeutic Areas at Boehringer Ingelheim, “Overall, the results of this survey align with our ongoing efforts as an organisation, highlighting the importance of optimising treatment and helping patients to maintain active lives.”
** Reposted with permission of Boehringer-Ingelheim **
An estimated 251 million people have been diagnosed with COPD, a progressive disease that limits airflow in and out of the lungs.2 There is no cure for COPD, but most patients can manage their COPD with the right medication and treatment plan.2
About the survey
This global patient survey was commissioned by Boehringer Ingelheim, and included 1,375 adults living with COPD aged 45 years and over. The online survey was fielded in 11 countries including China, Denmark, France, Germany, Italy, Japan, the Netherlands, Poland, Spain, the UK and the USA and patients were stratified by age (45–54, 55–64, ≥65 years). The objective of the survey was to assess the impact COPD has on patients’ lives.
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of 19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
Disrupted education due to covid will have far reaching effects for students worldwide.
In breaking #covidresearch & present 7 propositions for #SchoolLeaders responding to the pandemic.
Children born to mothers who had diabetes during pregnancy (Gestational diabetes) may age faster biologically
They could also be at an increased risk for obesity and high blood pressure, according to the study, led by
2 days ago
Just 3 female orange-bellied parrots returned to their breeding grounds in 2016 due to devastatingly low juvenile survival rates 🐦
Reporting in , experts state this marks the lowest point of a 10 year decline
3 days ago
Imagine a reusable face mask that is comfortable enough to wear all day 😷
Researchers from have designed a new mask intended to protect users from #COVID19 that stays in place without frequent adjustment
6 days ago
Could singing spread #COVID19? 🎤
A study finds more aerosol particles are produced by people singing – particularly loudly – therefore the disease reached further across the air than via normal communication.
7 days ago
Handgrip strength shown to identify people at high risk of type 2 diabetes ✊🏽
New and findings demonstrate handgrip strength could be a cost-effective early screening tool
8 days ago
A new study looking at 102 cats in #Wuhan shows more felines might be contracting #COVID19 than first believed
🐈 15% showed antibodies
🐈 11 had neutralizing antibodies, which successfully block the infection
🐈 No cats showed symptoms or died
13 days ago
#GreenGrowth, the idea that economic expansion will be offset by technological advances, has been suggested a solution to #climatechange. But is it a realistic possibility?
This important research by and weighs up the evidence 🍃
14 days ago
A new species of freshwater Crustacea has been discovered during an expedition of the desert Lut, known as the hottest place on Earth 🔥
The newly identified species belongs to the genus Phallocryptus
14 days ago
Sufferers of #arachnophobia 🕷 can take comfort in the results of this study!
Participants who were continuously but briefly exposed to images of #spiders 😱 experienced less fear by the end of the test.